NCT05730712 2026-02-06Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate CancerMayo ClinicPhase 2 Completed7 enrolled
NCT02480010 2015-09-18A Study of Pertuzumab in Participants With Prostate CancerHoffmann-La RochePhase 2 Terminated68 enrolled 18 charts
NCT00058539 2015-06-23Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate CancerGenentech, Inc.Phase 2 Completed42 enrolled 10 charts